EsaC Polypeptide Vaccine for Staphylococcus Infection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccines and treatments for Staphylococcus aureus infections are ineffective due to the emergence of antibiotic-resistant strains and limited immune response, necessitating a new approach to generate an immune response against staphylococcal pathogens.

Innovation Solution

The development of an immunogenic composition using the EsaC polypeptide, which is secreted by the Ess pathway, combined with other staphylococcal antigens or saccharides, to stimulate an immune response and provide protection against S. aureus infections.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are used to treat staphylococcal infections, then bacterial infections can be controlled, but antibiotic resistance develops making treatments ineffective

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidantibiotic resistance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent converts the harmful effect of bacterial infection into a beneficial immune response by using bacterial antigens (EsaC polypeptide) as vaccines. The harmful bacteria trigger the immune system to produce protective antibodies, transforming the pathogen's presence into a defense mechanism against future infections.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces an intermediary substance (EsaC polypeptide vaccine) that mediates between the host immune system and the pathogenic bacteria. This intermediary stimulates the immune system to produce protective responses without requiring direct exposure to harmful live bacteria or antibiotics.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If existing vaccines are used against Staphylococcus aureus, then some immune response is generated, but protection is limited and ineffective against resistant strains

Engineering Contradiction:

Improveprotective efficacyVSAvoidcoverage against resistant strains

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the parameter of vaccine antigen selection by identifying and using the EsaC polypeptide as the immunogenic component. This specific antigen parameter provides superior immune stimulation and broader protection compared to previous vaccine formulations that used different staphylococcal antigens.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If passive immunotherapy with polyclonal antisera is used, then some protection is provided, but the immune response is not sustained and requires repeated administration

Engineering Contradiction:

Improveshort-term protectionVSAvoidduration of immune protection

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent applies preliminary action by administering the EsaC polypeptide vaccine before infection occurs, allowing the immune system to develop active, long-lasting immunity in advance. This preventive vaccination approach creates sustained protection without requiring repeated therapeutic administrations after infection.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS8758765B2Compositions and methods related to Staphylococcal bacterium proteins

Publication Date: 2014.06.24 UNIVERSITY OF CHICAGO

AI summary

The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve an EsaC polypeptide.